E
Equillium
Biotechnology leveraging deep understanding of immunobiology to develop products for autoimmune and inflammatory disorders
About Equillium
Equillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to pioneer new products with a mission to dramatically improve the lives of patients with severe autoimmune and inflammatory diseases who continue to suffer with high unmet medical needs. By bringing treatments designed to restore the balance of the immune system, we hope to restore the balance of life for patients in need.
Read full description
Our lead product candidate, itolizumab, is a first-in-class monoclonal antibody that targets the CD6-ALCAM signaling pathway, which plays a central role in the activation and trafficking of pathogenic effector T cells that drive inflammation in a number of diseases. We believe itolizumab may have broad therapeutic utility and our current pipeline is focused on developing itolizumab as a best-in-class treatment for multiple severe immuno-inflammatory disorders – this includes acute graft-versus-host disease, SLE / lupus nephritis and uncontrolled asthma.
At a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- San Diego, United States
- Listing
- IPO 2018
- Employees
- 38
- Open positions
- None listed
- Dealroom signal
- 66.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 2 companies, latest Sep 2022
- Capital deployed
- —
- Preferred round
- ACQUISITION
Latest news
Press, funding announcements and product moves mentioning Equillium.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| PRIVATE PLACEMENT VCOther financing | Mar 2026 | $35M | — | RA Capital Management | ↗ |
| PRIVATE PLACEMENT VCOther financing | Aug 2025 | $30M | — | Woodline Partners · Coastlands Capital · Adage Capital · ADAR1 Capital Management | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $0 | — | −$24M | — |
| 2025 | $0 | -100% | −$24M | — |
| 2024 | $41M | +13.9% | −$7.6M | -18.4% |
| 2023 | $36M | +129% | −$12M | -33.6% |
| 2022 | $16M | 0% | −$16M | -101.4% |
| 2021 | $16M | 0% | −$38M | -239.8% |
| 2020 | $16M | — | −$30M | -187.5% |
Growth signals
Latest recorded traffic for Equillium is 5.6K monthly website visits, up 47.4% over the last three months. Equillium's team grew 8.6% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
MetacrineSan Diego, United StatesPrivately held biotech company
$26Mvaluation
BionizUnited StatesBiotechnology company focused on discovering small peptides and molecules for the treatment of autoimmune diseases and cancer
$329Mvaluation
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Mesa Verde Venture Partners
Series B and later1 investor entered at this stage
Decheng Capital
Other known investors8 additional known investors
Adage Capital
ADAR1 Capital Management- CCCoastlands Capital
Janus Henderson Investors
RA Capital Management
Woodline Partners
Alumni Ventures- BIBioBrit
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Equillium on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Equillium’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.